European Journal of Cardiovascular Medicine

This comparative study aimed to evaluate the impact of adding dexmedetomidine as an adjuvant to 0.75% isobaric ropivacaine in subarachnoid block for patients undergoing total abdominal hysterectomy. Methods: Fifty female patients within the age range of 35-65 years, classified as ASA grades I and II, were included in this study. They were divided into two groups: Group A (Dexmedetomidine) and Group B (Control). Various parameters were assessed, including the duration of sensory and motor blockade, duration of analgesia, and hemodynamic parameters. Results: The addition of dexmedetomidine significantly prolonged the duration of sensory blockade (142.20 ± 5.61 vs. 74.40 ± 3.91 minutes, p < 0.001), motor blockade (233.80 ± 4.15 vs. 140.80 ± 5.53 minutes, p < 0.001), and analgesia (358.80 ± 7.26 vs. 179.60 ± 7.76 minutes, p < 0.001) compared to the control group. Hemodynamic parameters remained stable, and the incidence of side effects was low. Conclusion: The addition of dexmedetomidine to ropivacaine in subarachnoid block provides prolonged sensory and motor blockade, leading to extended postoperative analgesia, without compromising hemodynamic stability. This approach presents a promising option for pain management in patients undergoing total abdominal hysterectomy.